Stifel Nicolaus Thinks Esperion’s Stock is Going to Recover


In a report issued on January 4, Derek Archila from Stifel Nicolaus maintained a Buy rating on Esperion (ESPR), with a price target of $45.00. The company’s shares closed last Wednesday at $25.40, close to its 52-week low of $23.90.

According to TipRanks.com, Archila is a 4-star analyst with an average return of 13.3% and a 51.3% success rate. Archila covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Madrigal Pharmaceuticals, and Apellis Pharmaceuticals.

Currently, the analyst consensus on Esperion is a Moderate Buy with an average price target of $61.00, which is a 143.7% upside from current levels. In a report issued on December 21, Jefferies also maintained a Buy rating on the stock with a $40.00 price target.

See today’s analyst top recommended stocks >>

Esperion’s market cap is currently $661.1M and has a P/E ratio of -6.50. The company has a Price to Book ratio of 72.55.

Based on the recent corporate insider activity of 14 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ESPR in relation to earlier this year. Most recently, in December 2020, Timothy Mayleben, the President & CEO of ESPR bought 10,700 shares for a total of $22,363.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Esperion Therapeutics, Inc. engages in the development and commercialization of oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol. It offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts